Obesity Unit, Endocrinology and Nutrition Department, Hospital Clinic Universitari, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Obesity Unit, Gastrointestinal Surgery Department, Hospital Clinic Universitari, Barcelona, Spain.
Gastroenterology. 2017 May;152(7):1780-1790. doi: 10.1053/j.gastro.2017.01.051. Epub 2017 Feb 11.
Metabolic and bariatric surgery (MBS) leads to weight loss in obese individuals and reduces comorbidities such as type 2 diabetes. MBS is superior to medical therapy in reducing hyperglycemia in persons with type 2 diabetes, and has been associated with reduced mortality and incidences of cardiovascular events and cancer in obese individuals. New guidelines have been proposed for the use of MBS in persons with type 2 diabetes. We review the use of MBS as a treatment for obesity and obesity-related conditions and, based on recent evidence, propose that health care systems make the appropriate changes to increase accessibility for eligible patients.
代谢和减重手术(MBS)可导致肥胖个体体重减轻,并降低 2 型糖尿病等合并症的发生。MBS 在降低 2 型糖尿病患者的高血糖方面优于药物治疗,并且与肥胖个体的死亡率以及心血管事件和癌症发生率降低相关。已经提出了用于 2 型糖尿病患者的 MBS 使用的新指南。我们回顾了 MBS 作为肥胖和肥胖相关疾病的治疗方法的使用,并根据最近的证据,建议医疗保健系统进行适当的调整,以增加符合条件的患者的可及性。